Medicinal composition for drug-induced neuropathy
    11.
    发明申请
    Medicinal composition for drug-induced neuropathy 审中-公开
    药物性神经病变药物组成

    公开(公告)号:US20060094685A1

    公开(公告)日:2006-05-04

    申请号:US10520772

    申请日:2003-07-09

    IPC分类号: A61K31/7072

    CPC分类号: C07H19/10 A61K31/7068

    摘要: The present invention relates to an agent for the prophylaxis or treatment of drug-induced neuropathy, which contains cytidine 5′-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of drug-induced neuropathy of the present invention shows a potent ameliorating effect on drug-induced neuropathy and is also superior in safety.

    摘要翻译: 本发明涉及含有胞苷5'-二磷酸胆碱(CDP-胆碱)作为活性成分的药物性神经病的预防或治疗药物。 用于预防或治疗本发明的药物性神经病的药剂显示出对药物诱发的神经病变有效的改善效果,并且安全性也优异。

    Agent against psychosocial stresses
    12.
    发明授权
    Agent against psychosocial stresses 失效
    针对社会心理压力的代理人

    公开(公告)号:US08017594B2

    公开(公告)日:2011-09-13

    申请号:US12302044

    申请日:2007-06-26

    IPC分类号: A01N43/04 A61K31/70

    摘要: To provide a novel anti-psychosocial stress agent which is highly safety and can be continuously taken, more particularly, a novel anti-psychosocial stress agent which prevents or alleviates psychosocial stress.The invention provides an anti-psychosocial stress agent containing, as an active ingredient, uridylic acid, uridine, or uracil. Since uridylic acid, uridine, or uracil, which is an active ingredient of the anti-psychosocial stress agent of the present invention, is inexpensively available and is a biological component, the agent exhibits high safety and can be continuously taken. Therefore, the anti-psychosocial stress agent of the present invention is effective for mitigating, alleviating, or relieving psychosocial stress, which is an issue in modern society. When the anti-psychosocial stress agent is taken before development of symptoms associated with psychosocial stress, the symptoms can be prevented. The anti-stress effect of the agent is superior to that of GABA, which has become of interest and has been incorporated into, for example, foods.

    摘要翻译: 提供一种高度安全性,可以持续服用的新型抗心理应激药,更具体地说,是一种防止或缓解心理社会压力的新型抗心理应激剂。 本发明提供一种抗心理应激剂,其含有尿苷酸,尿苷或尿嘧啶作为活性成分。 由于作为本发明的抗心理应激药物的活性成分的尿苷酸,尿苷或尿嘧啶是廉价的,是生物成分,所以该试剂表现出高安全性并且可以连续服用。 因此,本发明的抗心理应激药对减轻,缓解或缓解心理社会压力是有效的,这是现代社会的一个问题。 在心理社会压力症状发展前采取抗心理应激药物时,可以预防症状。 该试剂的抗应激作用优于已经成为感兴趣且已经并入到例如食品中的GABA的抗应激作用。

    AGENT AGAINST PSYCHOSOCIAL STRESSES
    13.
    发明申请
    AGENT AGAINST PSYCHOSOCIAL STRESSES 失效
    代理人心理压力

    公开(公告)号:US20090118224A1

    公开(公告)日:2009-05-07

    申请号:US12302044

    申请日:2007-06-26

    摘要: To provide a novel anti-psychosocial stress agent which is highly safety and can be continuously taken, more particularly, a novel anti-psychosocial stress agent which prevents or alleviates psychosocial stress.The invention provides an anti-psychosocial stress agent containing, as an active ingredient, uridylic acid, uridine, or uracil. Since uridylic acid, uridine, or uracil, which is an active ingredient of the anti-psychosocial stress agent of the present invention, is inexpensively available and is a biological component, the agent exhibits high safety and can be continuously taken. Therefore, the anti-psychosocial stress agent of the present invention is effective for mitigating, alleviating, or relieving psychosocial stress, which is an issue in modern society. When the anti-psychosocial stress agent is taken before development of symptoms associated with psychosocial stress, the symptoms can be prevented. The anti-stress effect of the agent is superior to that of GABA, which has become of interest and has been incorporated into, for example, foods.

    摘要翻译: 提供一种高度安全性,可以持续服用的新型抗心理应激药,更具体地说,是一种防止或缓解心理社会压力的新型抗心理应激剂。 本发明提供一种抗心理应激剂,其含有尿苷酸,尿苷或尿嘧啶作为活性成分。 由于作为本发明的抗心理应激药物的活性成分的尿苷酸,尿苷或尿嘧啶是廉价的,是生物成分,所以该试剂表现出高安全性并且可以连续服用。 因此,本发明的抗心理应激药对减轻,缓解或缓解心理社会压力是有效的,这是现代社会的一个问题。 在心理社会压力症状发展前采取抗心理应激药物时,可以预防症状。 该试剂的抗应激作用优于已经成为感兴趣且已经并入到例如食品中的GABA的抗应激作用。

    Pharmaceutical composition for diabetic neuropathy
    14.
    发明授权
    Pharmaceutical composition for diabetic neuropathy 失效
    糖尿病性神经病的药物组合物

    公开(公告)号:US07074773B2

    公开(公告)日:2006-07-11

    申请号:US11098439

    申请日:2005-04-05

    CPC分类号: C07H19/10 A61K31/7068

    摘要: The present invention relates to an agent for the prophylaxis or treatment of diabetic neuropathy, which contains cytidine 5′-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of diabetic neuropathy of the present invention is effective for neuropathy mainly caused by metabolic disturbance of carbohydrate and is also superior in safety. Neuropathy includes peripheral neuropathy and dysautonomia. CDP-choline is effective even by oral administration.

    摘要翻译: 本发明涉及含有胞苷5'-二磷酸胆碱(CDP-胆碱)作为活性成分的预防或治疗糖尿病性神经病的药剂。 用于预防或治疗本发明的糖尿病性神经病的药剂对于主要由碳水化合物的代谢紊乱引起的神经病有效,并且安全性也优异。 神经病包括周围神经病和自主神经病。 CDP-胆碱甚至通过口服给药也是有效的。

    2-alkynyl-N9-propargyladenine and medicinal use thereof
    15.
    发明授权
    2-alkynyl-N9-propargyladenine and medicinal use thereof 有权
    2-炔基-N9 - 炔丙基腺嘌呤及其医药用途

    公开(公告)号:US08791126B2

    公开(公告)日:2014-07-29

    申请号:US13989647

    申请日:2011-11-24

    IPC分类号: C07D473/34

    摘要: In the present invention, a novel 2-alkynyl-N9-propargyladenine represented by formula (I) wherein R1 represents a halogen atom, a furyl group, or a triazolyl group; R2 and R3 each represents a hydrogen atom or a C1-8 alkyl group, or form a cycloalkyl group by bonding to each other; and X represents a hydrogen atom or a hydroxyl group, or a pharmaceutically acceptable salt thereof, has a stronger and longer-lasting effect as a therapeutic agent for Parkinsonian syndromes.

    摘要翻译: 在本发明中,由式(I)表示的新的2-炔基-N9-炔丙基腺嘌呤,其中R1表示卤素原子,呋喃基或三唑基; R2和R3各自表示氢原子或C1-8烷基,或者通过彼此键合形成环烷基; X表示氢原子或羟基或其药学上可接受的盐作为帕金森综合征的治疗剂具有更强的和更持久的作用。

    Medicinal composition for diabetic neuropathy
    16.
    发明授权
    Medicinal composition for diabetic neuropathy 失效
    糖尿病性神经病变药物组成

    公开(公告)号:US06924272B2

    公开(公告)日:2005-08-02

    申请号:US10381716

    申请日:2002-09-03

    CPC分类号: C07H19/10 A61K31/7068

    摘要: The present invention relates to an agent for the prophylaxis or treatment of diabetic neuropathy, which contains cytidine 5′-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of diabetic neuropathy of the present invention is effective for neuropathy mainly caused by metabolic disturbance of carbohydrate and is also superior in safety. Neuropathy includes peripheral neuropathy and dysautonomia. CDP-choline is effective even by oral administration.

    摘要翻译: 本发明涉及含有胞苷5'-二磷酸胆碱(CDP-胆碱)作为活性成分的预防或治疗糖尿病性神经病的药剂。 用于预防或治疗本发明的糖尿病性神经病的药剂对于主要由碳水化合物的代谢紊乱引起的神经病有效,并且安全性也优异。 神经病包括周围神经病和自主神经病。 CDP-胆碱甚至通过口服给药也是有效的。

    Pharmaceutical composition for diabetic neuropathy
    18.
    发明申请
    Pharmaceutical composition for diabetic neuropathy 失效
    糖尿病性神经病的药物组合物

    公开(公告)号:US20050171051A1

    公开(公告)日:2005-08-04

    申请号:US11098439

    申请日:2005-04-05

    CPC分类号: C07H19/10 A61K31/7068

    摘要: The present invention relates to an agent for the prophylaxis or treatment of diabetic neuropathy, which contains cytidine 5′-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of diabetic neuropathy of the present invention is effective for neuropathy mainly caused by metabolic disturbance of carbohydrate and is also superior in safety. Neuropathy includes peripheral neuropathy and dysautonomia. CDP-choline is effective even by oral administration.

    摘要翻译: 本发明涉及含有胞苷5'-二磷酸胆碱(CDP-胆碱)作为活性成分的预防或治疗糖尿病性神经病的药剂。 用于预防或治疗本发明的糖尿病性神经病的药剂对于主要由碳水化合物的代谢紊乱引起的神经病有效,并且安全性也优异。 神经病包括周围神经病和自主神经病。 CDP-胆碱甚至通过口服给药也是有效的。

    Purine compounds and xanthine oxidase inhibitors
    20.
    发明授权
    Purine compounds and xanthine oxidase inhibitors 失效
    嘌呤化合物和黄嘌呤氧化酶抑制剂

    公开(公告)号:US5990118A

    公开(公告)日:1999-11-23

    申请号:US894474

    申请日:1997-08-20

    摘要: Purine or triazolopurine compounds are disclosed represented by formula (I) or (II): ##STR1## wherein R.sup.1 and R.sup.4 represent each hydrogen, halogeno, hydroxy, mercapto, or amino; R.sup.2 represents alkyl or aryl; and R.sup.3 and R.sup.5 represent each hydrogen, alkyl, or aryl; and pharmaceutical compositions comprising these compounds as xanthine oxidase inhibitors, remedies for hyperuricemia, or remedies or preventive agents for gout.

    摘要翻译: PCT No.PCT / JP96 / 00391 Sec。 371日期1997年8月20日 102(e)日期1997年8月20日PCT 1996年2月21日PCT PCT。 WO96 / 26208 PCT出版物 日期:1996年8月29日公开了由式(I)或(II)表示的嘌呤或三唑并嘌呤化合物:其中R1和R4代表各自的氢,卤代,羟基,巯基或氨基; R2代表烷基或芳基; 并且R 3和R 5表示各自的氢,烷基或芳基; 以及包含这些化合物作为黄嘌呤氧化酶抑制剂的药物组合物,高尿酸血症的补救措施,或痛风的补救措施或预防剂。